Identification of human tumor antigens and immunotherapy
Identification of human tumor antigens and immunotherapy
批准号:
11694301
负责人:
SATO Noriyuki
金额:
$8.28万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our studies indicated that 1) inhibitors of apoptosis (IAP) protein were expressed preferentially in neoplastic cells but not in normal tissues. Such IAP, particulary, survivin-and livin-derived HLA-A24-restricted peptides could be immunogenic to cancer patients. 2) Recoverin protein that normally expresses in retina was also detected in more than 50 % of cancer cells and cancer tissues. Recoverin-derived HLA-A24-restricted peptide could also specifically induce CTL in the cancer patients of various tissue origins. 3) SYT-SSX chromosomal translocation (X;18) fusion protein was expressed specifically in approximately 95 % of synovial sarcomas. This protein-derived HLA-A24-restricted peptide could induce antigen-specific CTL, and tetramer study suggested that the precursor of these CTL was detected more frequently in patients with lung metastasis of this tumor. These data implied that above peptides may be useful in human cancer immunotherapy.We also assessed the role of molecular chaperone, hsc73, in the transport of antigenic peptide into the ER. The data indicated that N-terminus-extended peptides that showed high, but not low, affinity to hsc73 could enter into the ER. This observation is important in determining tumor vaccines, because hsc73-binding peptides may be preferentially associated with MHC class I molecules.
期刊论文(36)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kikuchi,K.,and Sato,N.: "Gann Monogr.J.Cancer Res."Cell-mediated Immunity to autologous cancer.Rationale of immunotherapy of human cancer with CTL.. 12 (1999)
Kikuchi,K.,和 Sato,N.:“Gann Monogr.J.Cancer Res.”细胞介导的自体癌症免疫。用 CTL 进行人类癌症免疫治疗的基本原理.. 12 (1999)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Maeda, A., Ohguro, H., Nabeta, Y., Kuroki, Y., Sato, N.et al.: "Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, cancer associated retinopathy antige, to achieve a clinical better prognosis in a paraneoplastic syndrome"Eur.
Maeda, A.、Ohguro, H.、Nabeta, Y.、Kuroki, Y.、Sato, N.等人:“鉴定人类抗肿瘤细胞毒性 T 淋巴细胞恢复蛋白、癌症相关视网膜病变抗原的表位,以实现更好的临床
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Maeda, A., Ohguro, H., Nabeta, Y., Hirohashi, Y., Sahara, H., Maeda, T., Wada, Y., Sato, T., Chuns, Y., Nishimura, Y., Kuroki, Y., and Sato, N.: "Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, cancer associated retinopath
前田,A.,大黑,H.,Nabeta,Y.,广桥,Y.,撒哈拉,H.,前田,T.,和田,Y.,佐藤,T.,春斯,Y.,西村,Y.,
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sahara, H., Nabeta, Y., Torigoe, T., Hirohashi, Y., Ichimiya, S., Wada, Y., Takehashi, N., Jimbow, K., Yajima, T., Watanabe, N., Kikuchi, K., and Sato, N.: "A gene encoding human gastric signete ring cell carcinoma antigen recognized by HLA-A31-restricted
撒哈拉,H.,Nabeta,Y.,Torigoe,T.,广桥,Y.,Ichimiya,S.,和田,Y.,竹桥,N.,Jimbow,K.,矢岛,T.,渡边,N.,
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sato, Y., Nabeta, Y., Tsukahara, T., Hirohashi, Y., Rone. S., Maeda, A., Sajara, H., Ikeda, H., Torigoe, T., Ichimiya, S., Wada, T., Yamashita, T., Hiraga, R, Kawai, A., Ishii, T., Araki, N., Kmyoui, A., Matsumoto, S., Umeda, T., Ishii, S., Kawaguchi, S.
佐藤,Y.,Nabeta,Y.,冢原,T.,广桥,Y.,罗恩。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 34 条
Extracellular Hsp90 plays a pivotal role in innate immunity and adaptive immunity
-
批准号:24659165
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2012
-
负责人:SATO Noriyuki
-
依托单位:
A study on the economic structure of Mongolia in the Qing era from the viewpoint of the Chinese commercial district "Mai-mai-cheng"
-
批准号:23720341
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.75万
-
财政年份:2011
-
负责人:SATO Noriyuki
-
依托单位:
patho-physiologic role of HSP90 in the aseptic inflammatory process
-
批准号:22659075
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$1.98万
-
财政年份:2010
-
负责人:SATO Noriyuki
-
依托单位:
Molecular immunopathology of human cancer stem cell
-
批准号:21249025
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$29.45万
-
财政年份:2009
-
负责人:SATO Noriyuki
-
依托单位:
Development of therapeutic cancer vaccine
-
批准号:17016061
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$29.57万
-
财政年份:2005
-
负责人:SATO Noriyuki
-
依托单位:
Immune response and escape in human cancers
-
批准号:16209013
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$29.79万
-
财政年份:2004
-
负责人:SATO Noriyuki
-
依托单位:
Human cancer vaccines
-
批准号:12213116
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$32.19万
-
财政年份:2000
-
负责人:SATO Noriyuki
-
依托单位:
The mechanism of the susceptibility to infection in diabetes and the new management
-
批准号:09671023
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.32万
-
财政年份:1997
-
负责人:SATO Noriyuki
-
依托单位:
HLA-A31-restricted gastric tumor antigenic peptide and clinical application
-
批准号:09557019
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.02万
-
财政年份:1997
-
负责人:SATO Noriyuki
-
依托单位:
T Cell Response with Stress Proteins
-
批准号:09470067
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.19万
-
财政年份:1997
-
负责人:SATO Noriyuki
-
依托单位:
T cell response against stress proteins
-
批准号:07457063
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.8万
-
财政年份:1995
-
负责人:SATO Noriyuki
-
依托单位:
Establishment of recipient cells for oncogene detection and analysis of transformation-associated cell surface antigen expression
-
批准号:61570180
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.6万
-
财政年份:1987
-
负责人:SATO Noriyuki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
FGF21通过CTL1介导的胆碱稳态调控线粒体自噬对帕金森病的保护机制研究
-
批准号:MS25H310003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李晨
-
依托单位:
S1P诱导LSEC分泌IL-12调控HBV特异性CTL应答的机制及作为HBeAg阴性慢性乙型肝炎急性发作分型标志物的研究
-
批准号:2025JJ50652
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:吴伟民
-
依托单位:
CD4+ CTL通过杀伤抗原呈递细胞减轻放射性脑损伤的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:石中山
-
依托单位:
E3泛素连接酶Ctl-b通过DBC1/SIRT1轴调控小胶质细胞NLRP3炎性小体在老年PND中的作用及机制研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:陈勇
-
依托单位:
AuNPs@CTLA-4/Nb16-Fc多臂纳米抗体增强DC/肿瘤融合疫苗诱导特异性CTL抗癌研究
-
批准号:82360559
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:刘爱群
-
依托单位:
肿瘤细胞微颗粒诱导肥大细胞活化介导CTL细胞耗竭促恶性胸腔积液进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:
-
依托单位:
CTCFL调控IL-10抑制CD4+CTL旁观者激活促口腔鳞状细胞癌新辅助免疫治疗抵抗机制研究
-
批准号:82373325
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:夏荣辉
-
依托单位:
肿瘤细胞TMEM87a介导CTL杀伤抵抗的机制研究
-
批准号:82302075
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李经
-
依托单位:
恶性胸腔积液肿瘤细胞微颗粒中干细胞因子刺激肥大细胞脱颗粒介导CTL细胞耗竭的作用及机制研究
-
批准号:--
-
项目类别:--
-
资助金额:30万元
-
批准年份:2023
-
负责人:张帅
-
依托单位:
具备CTL增强效应的IBV优势表位对清除变异株的作用及机制研究
-
批准号:32302906
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:夏静
-
依托单位: